Core Viewpoint - The A-share market has shown significant upward movement, with the Shanghai Composite Index surpassing 3800 points and the Sci-Tech Innovation 50 Index rising over 8%, marking a three-year high. Key sectors such as computing power, semiconductors, and securities have led the gains, with notable stocks like Cambrian and CloudWalk hitting their daily limits [1][2]. Group 1: Market Performance - On August 22, the A-share market experienced a strong rally, with the Shanghai Composite Index reaching above 3800 points and the Sci-Tech Innovation 50 Index increasing by over 8% [1]. - The computing power sector saw a broad surge, with stocks like CloudWalk hitting their daily limit, while semiconductor and securities sectors also performed well [1][2]. Group 2: Dividend Announcements - As of August 21, over 200 A-share companies have announced mid-term dividend plans, totaling over 130 billion yuan, with 14 companies planning dividends exceeding 1 billion yuan [3][5]. - China Mobile leads with a proposed dividend of 54.083 billion yuan, followed by China Telecom at 16.581 billion yuan, and China Petroleum at 10.67 billion yuan [5][6]. Group 3: High Dividend Companies - Notably, 15 companies have announced dividend ratios exceeding 100%, with Shuoshi Biological's ratio reaching an extraordinary 7142.28%, despite a net profit of only 399 million yuan [11][12]. - Companies like Jibite and Fuyou Glass have also reported significant dividends, with Jibite proposing a cash dividend of 66 yuan per 10 shares, amounting to 4.74 billion yuan [6][7]. Group 4: Dividend Yield - As of August 21, 60 companies have a dividend yield exceeding 3%, with 20 companies yielding over 5%. Notably, Thinking Control has a yield of over 10% [13][14]. - The dividend yield reflects the company's profitability and cash flow stability, indicating a potential for sustainable dividends [15].

Group 1 - On August 21, a total of 3,713 stocks in the A-share market received financing funds, with 570 stocks having a buying amount exceeding 100 million yuan [1] - The top three stocks by financing buying amount were ZTE Corporation, Dongfang Wealth, and Inspur Information, with amounts of 3.048 billion yuan, 2.399 billion yuan, and 2.267 billion yuan respectively [1] - Four stocks had financing buying amounts accounting for over 30% of the total transaction amount on that day, with Shuoshi Biology, Meishuo Technology, and Lijure Energy leading at 33.0%, 32.97%, and 31.97% respectively [1] Group 2 - There were 44 stocks with a net financing buying amount exceeding 100 million yuan, with the top three being Guiding Compass, Inspur Information, and China Unicom, which had net buying amounts of 530 million yuan, 406 million yuan, and 373 million yuan respectively [1]

Group 1 - The core viewpoint of the news is that Shuoshi Biotechnology (688399) has experienced a decline in stock price and significant net outflow of funds, alongside a decrease in revenue and profit in its latest financial report [1][3] - As of August 19, 2025, the stock closed at 65.06 yuan, down 1.03%, with a turnover rate of 2.64% and a trading volume of 22,100 hands, amounting to 143 million yuan in transaction value [1] - The company reported total revenue of 176 million yuan for the first half of 2025, a year-on-year decrease of 1.05%, and a net profit attributable to shareholders of 3.99 million yuan, down 86.35% year-on-year [1] Group 2 - The company has a current ratio of 4.181, a quick ratio of 4.078, and a debt-to-asset ratio of 16.13%, indicating a strong liquidity position [1] - Shuoshi Biotechnology has made investments in 15 companies and participated in 1,760 bidding projects, showcasing its active engagement in the market [2] - The company holds 209 trademark registrations and 180 patents, along with 244 administrative licenses, reflecting its focus on intellectual property and regulatory compliance [2]

Core Points - The company is holding its first extraordinary general meeting of shareholders in 2025 to ensure the rights of all shareholders and maintain order during the meeting [1] - The meeting will include a discussion and voting on key proposals, including a profit distribution plan and the reappointment of an accounting firm [6][9] Meeting Procedures - Shareholders and their representatives must arrive 30 minutes before the meeting to complete registration and present necessary documents [2] - The meeting will follow a predetermined agenda for discussion and voting on proposals [3] - Shareholders have the right to speak, inquire, and vote, but must adhere to the meeting's order and time limits for speaking [4][5] Voting and Proposals - Voting will be conducted both on-site and online, with specific time frames for each method [5] - The first proposal involves a profit distribution plan, proposing a cash dividend of 34.00 RMB per 10 shares, totaling approximately 285.16 million RMB [6] - The second proposal is to reappoint Lixin Certified Public Accountants for the 2025 financial year, with the management authorized to negotiate audit fees [8][9]

Core Viewpoint - The company, Jiangsu Shuoshi Biotechnology Co., Ltd., is holding a half-year performance and cash dividend briefing session on August 28, 2025, to communicate its operational results and financial status for the first half of 2025 with investors [2][4]. Group 1: Meeting Details - The meeting is scheduled for August 28, 2025, from 14:00 to 15:00 [2][3]. - It will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3]. - Investors can submit questions from August 21 to August 27, 2025, via the company's email or the Roadshow Center's website [3][4]. Group 2: Participants - Key participants include the Chairman and General Manager, Wang Guoqiang, and other executives such as Liu Zhonghua, Hu Yuanyuan, and Meng Yuanyuan [2][3]. - Independent director Liu Xiaolun will also be present, although adjustments to the participant list may occur due to special circumstances [2]. Group 3: Investor Participation - Investors can join the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [2][3]. - The company will address commonly asked questions during the session [2][3]. Group 4: Additional Information - After the meeting, investors can access the details and main content of the briefing through the Shanghai Stock Exchange Roadshow Center [4].

江苏硕世生物科技股份有限公司 2025 年第一次临时股东大会会议材料 证券简称：硕世生物 证券代码：688399 江苏硕世生物科技股份有限公司 2025 年第一次临时股东大会 会议材料 2025 年 8 月 27 日 江苏硕世生物科技股份有限公司 2025 年第一次临时股东大会会议材料 江苏硕世生物科技股份有限公司 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则》以及《江苏硕世生物科技股份有限公司章程》《江苏硕世 生物科技股份有限公司股东大会议事规则》等相关规定，特制定 2025 年第一次 临时股东大会须知。 一、为保证本次大会的严肃性和正常秩序，切实维护与会股东（或股东代理 人）的合法权益，除出席会议的股东（或股东代理人）、公司董事、监事、高级 管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他无关人员进 入会场。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示证券账户卡、身份证明文件或营业执照复印件（加 ...

证券代码：688399 证券简称：硕世生物 公告编号：2025-029 江苏硕世生物科技股份有限公司 关于召开 2025 年半年度业绩 暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 08 月 21 日（星期四）至 08 月 27 日（星期三） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 sssw@s-sbio.com 进行提问。公司将在说明会上对投资者普 遍关注的问题进行回答。 江苏硕世生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 9 日发布公司 2025 年半年度报告，为便于广大投资者更全面 深入地了解公司 2025 年半年度经营成果、财务状况及利润分配事项， 公司计划于 2025 年 08 月 28 日（星期四）14:00-15:00 举行 2025 年 半年度业绩暨现金分红说明会，就投资者关心的问题进行交流。 会议召开时间：2025 年 08 月 28 日（星期四）14:00-15:00 会议召开地 ...

Core Viewpoint - The financial performance of Shuoshi Biological (688399) in the first half of 2025 is disappointing, with significant declines in key financial metrics [2][9]. Financial Performance Overview - Total revenue for the reporting period was 176 million yuan, a year-on-year decrease of 1.05% [2]. - Net profit attributable to shareholders was only 3.99 million yuan, down 86.35% year-on-year [2]. - The net profit after deducting non-recurring items recorded a loss of 28.05 million yuan, a year-on-year decline of 1219.78% [2]. Quarterly Data - In the second quarter, total revenue was 83.97 million yuan, a decrease of 2.73% year-on-year [3]. - The net profit attributable to shareholders for the second quarter was -8.83 million yuan, an increase of 18.48% year-on-year [3]. - The net profit after deducting non-recurring items for the second quarter was -22.47 million yuan, down 32.17% year-on-year [3]. Key Financial Indicators Analysis - The company's profitability has significantly weakened, with a gross margin of 62.44%, down 8.35 percentage points year-on-year [4]. - The net profit margin was 2.27%, a decrease of 86.2 percentage points year-on-year [4]. - Earnings per share were 0.05 yuan, down 85.29% year-on-year [4]. Costs and Expenses - Total sales, management, and financial expenses amounted to 96.32 million yuan, accounting for 54.86% of revenue, an increase of 8.66 percentage points year-on-year [5]. - The increase in financial expenses was primarily due to the company's shift in investment strategy, reducing bank deposits and thus decreasing interest income [5]. Asset Status - The company's cash and cash equivalents were 496 million yuan, a decrease of 69.37% year-on-year [6]. - Accounts receivable stood at 65.70 million yuan, down 7.94% year-on-year [6]. - Interest-bearing liabilities increased to 404 million yuan, up 28.43% year-on-year [6]. - The net cash flow from operating activities was negative, with operating cash flow per share at -0.01 yuan, a decrease of 100.54% year-on-year [6]. Main Business Composition - The main source of revenue for the company is diagnostic reagents, generating 151 million yuan, accounting for 85.89% of total revenue, with a gross margin of 68.36% [7]. - Revenue from purchased instruments and materials, testing instruments, testing services, and other businesses accounted for 7.19%, 3.84%, 2.24%, and 0.84% respectively, with significant variations in gross margins, particularly testing services which had a negative gross margin of -9.54% [7]. Operational Review - The company focuses on the research, production, and sales of in vitro diagnostic reagents and related testing instruments, while also expanding into the in vitro testing services sector [8]. - Despite significant investment in research and development, which accounted for 23.15% of revenue, overall performance has declined [8]. - International revenue grew by 31.32% year-on-year, indicating potential for market expansion, while domestic revenue was 169 million yuan, accounting for 96.05% of total revenue, with a gross margin of 62.03%, lower than the international business margin of 72.49% [8].

硕世生物首次公开发行股票募集资金总额为68,579.48万元，募集资金净额为61,293.36万元，较原计划多 21,028.36万元。硕世生物于2019年11月29日披露招股说明书显示，该公司拟募集资金40,265万元，计划 用于硕世生物泰州总部产业园项目。 硕世生物首次公开发行股票的发行费用总额为7,286.12万元(发行费用均为含税金额)，其中，保荐及承 销费用为5,493.46万元。 2025年6月7日，硕世生物公告以每10股转增4.8股，股权登记日2025年6月12日，除权除息日2025年6月 13日，红股上市日2025年6月13日。 中国经济网北京8月11日讯硕世生物(688399.SH)近日披露2025年半年度报告。报告期内，该公司实现营 业收入1.76亿元，同比下降1.05%；实现归属于上市公司股东的净利润399.26万元，同比下降86.35%； 实现归属于上市公司股东的扣除非经常性损益的净利润-2804.79万元，上年同期为-212.52万元；经营活 动产生的现金流量净额为-57.56万元，上年同期为7428.90万元。 2024年，硕世生物实现营业收入3.50亿元，同比下降13.29%；归 ...

Group 1 - Tsinghua Unigroup's control will change as Hunan Sailuxian will acquire approximately 58.61 million shares from its controlling shareholder, Tsinghua Technology Service Co., Ltd, leading to a shift in control of Tsinghua Unigroup [1] - The new controlling shareholder will need to stabilize the company's operations amidst industry consolidation, and investors should pay attention to future asset integration and the new shareholder's resource injection capabilities, with potential short-term stock price volatility [1] Group 2 - Shuoshi Bio reported a revenue of 176 million yuan, a year-on-year decrease of 1.05%, and a net profit attributable to shareholders of 3.99 million yuan, down 86.35% year-on-year, primarily due to the deepening of centralized procurement in the in vitro diagnostic industry and an increase in the VAT rate to 13% [2] - The decline in net profit is attributed to pressure on product prices from industry procurement, a significant drop in gross margin, and a 13.11% reduction in R&D investment, which may weaken long-term competitiveness [2] Group 3 - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotech, received FDA approval to conduct Phase I clinical trials for HLX43, a targeted PD-L1 antibody-drug conjugate for thymic cancer, marking a significant step in the internationalization of innovative drugs [3] - The drug's dual advantages of immune modulation and precise targeting position it competitively in the global market, with the potential to fill a treatment gap for thymic cancer if subsequent data is positive [3] Group 4 - Junshi Biosciences announced that the National Medical Products Administration has accepted the application for the 13th indication of its PD-1 monoclonal antibody, Toripalimab, for use in combination with HER2 ADC for patients with locally advanced or metastatic urothelial carcinoma expressing HER2 [4] - This combination is expected to further strengthen Junshi's differentiated positioning in the PD-1 market and enhance collaboration with Rongchang Bio on ADC development [4]